Myokardia Inc (MYOK)’s Trend Up, Especially After Today’s Strong Session

September 17, 2017 - By Winifred Garcia

The stock of Myokardia Inc (NASDAQ:MYOK) is a huge mover today! The stock increased 4.65% or $2.05 on September 15, reaching $46.15. About 1.30M shares traded or 21.50% up from the average. Myokardia Inc (NASDAQ:MYOK) has risen 11.16% since September 17, 2016 and is uptrending. It has underperformed by 5.54% the S&P500.
The move comes after 7 months positive chart setup for the $1.61 billion company. It was reported on Sep, 17 by We have $47.53 PT which if reached, will make NASDAQ:MYOK worth $48.30M more.

Investors wait Myokardia Inc (NASDAQ:MYOK) to report on November, 6. its quarterly earnings Wall Street analysts expect $-0.41 earnings per share, down $0.06 or 17.14 % from last year’s $-0.35 same quarter earnings. Myokardia Inc’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.41 EPS reproted in the previous quarter,

Myokardia Inc (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. Wells Fargo initiated Myokardia Inc (NASDAQ:MYOK) on Friday, December 4 with “Outperform” rating. The firm has “Outperform” rating by Credit Suisse given on Monday, November 23. The firm has “Outperform” rating by Wedbush given on Monday, November 23. The firm earned “Outperform” rating on Monday, November 23 by Cowen & Co. The stock of Myokardia Inc (NASDAQ:MYOK) has “Outperform” rating given on Wednesday, July 20 by BMO Capital Markets.

More recent Myokardia Inc (NASDAQ:MYOK) news were published by: which released: “MyoKardia to Present at Two Upcoming Investor Conferences in September” on August 30, 2017. Also published the news titled: “MyoKardia hits life high after encouraging heart drug data” on August 07, 2017.‘s news article titled: “MyoKardia Appoints David Meeker, MD, to Board of Directors” with publication date: April 18, 2017 was also an interesting one.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.61 billion. The Firm focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It currently has negative earnings. The Firm is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.